System and method for detecting toxin activity
By using HEPES, NaCl, DTT, surfactant or Zn(OAc)2 system combined with FRET method in toxin detection, the existing problems of low efficiency and inaccurate quantification are solved, and the activity of toxins is achieved efficient and accurate determination.
Patent Information
- Application Number
- CN202410700813.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
The existing toxin enzyme activity detection methods are inefficient and inaccurate in quantification, so they cannot accurately determine the biological activity of toxins, especially the detection methods for Clostridium toxins and their analogs are insufficient.
A system containing HEPES, NaCl, DTT, surfactant or Zn(OAc)2 was used, combined with the fluorescence resonance energy transfer (FRET) method, substrate protein was detected by enzyme-clearing toxins, and fluorescence signal changes were calculated. The enzyme activity of toxins improves the accuracy and efficiency of detection.
It is more convenient, high throughput, and efficient and accurate to detect toxins (such as Botox type A), and can effectively and accurately determine the enzyme activity of toxins.
Smart Images

Figure CN119061113A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of enzyme activity determination, and specifically relates to a system and method for detecting toxin activity, and more specifically relates to a system and method for detecting botulinum toxin. Background Art
[0002] Some toxins, such as the light chain of Clostridial toxins, can cut the SNARE family proteins related to vesicle transport, making it impossible for nerve cells to complete the neurotransmitter transport function, thereby blocking the transmission of nerve signals. Blocked nerve cell signal transmission will lead to inhibition of muscle cell contraction, obstruction of pain and itch transmission, thereby achieving beauty, analgesia, antipruritic and other effects. Therefore, the enzymatic activity of the toxin light chain is crucial for the function of such toxins. Detecting the enzymatic activity of the toxin light chain is equivalent to verifying the enzymatic activity of the toxin. At present, there are many studies on Clostridial toxins and their analogs, but there are very few methods for detecting the enzymatic activity of Clostridial toxins and their analogs. The early detection methods were mainly based on the antigenicity of Clostridial toxins and developed antibody detection. The most widely used one is enzyme-linked immunosorbent assay. During the determination, Clostridial toxins and their analogs are fixed to the enzyme-linked immunosorbent plate, and the labeled Clostridial toxins and their analogs are used for detection. The results are amplified by enzymatic reaction, thereby realizing the determination of Clostridial toxins and their analogs. However, this method can only detect the biomass of Clostridial toxins, and cannot detect the biological activity of Clostridial toxins. In recent years, enzyme activity detection methods based on the light chain of Clostridial toxins and their analogs have emerged. One type is fluorescence detection, which mainly uses the luminescence principle of fluorescent proteins to connect fluorescent proteins to substrates and judge the strength of enzyme activity by fluorescence changes. The other type is to detect the substrate residue after enzyme cleavage, mainly through the polyacrylamide gel running method to obtain the residual substrate after enzyme cleavage. This method requires quantitative quantification based on grayscale, which is inaccurate and has a long reaction time. In general, these methods are inefficient in detecting enzyme activity and cannot accurately measure enzyme activity. Therefore, it is necessary to design a system and method for detecting toxin activity that is simple to operate, efficient, and quantitatively accurate. Summary of the invention
[0003] The first aspect of the present invention provides a system for detecting toxin activity, comprising one or more of the following components: HEPES, NaCl, DTT, a surfactant or Zn(OAc) 2 .
[0004] Further preferably, the surfactant is selected from one or more of triton x-100, SDS, Span or Tween; more preferably, the surfactant is selected from Tween.
[0005] More preferably, the components further include an enzymatic toxin and a substrate protein that are active when cleaved by a first specific protease.
[0006] Further preferably, the toxin is selected from Clostridial toxins.
[0007] Further preferably, the toxin is selected from botulinum toxin.
[0008] Further preferably, the toxin is selected from botulinum toxin type A, B, C, D, E, F or G
[0009] Further preferably, the toxin is selected from botulinum toxin type A.
[0010] Further preferably, the first specific protease is selected from one or more of epidermis-specific kallikreins (KLKs), SASPase proteases, Caspase proteases, and Furin proteases.
[0011] Further preferably, the KLKs are selected from any one or more of KLK1 to KLK15.
[0012] Further preferably, the KLKs include KLK1, KLK2, KLK3, KLK4, KLK5, KLK6, KLK7, KLK8, KLK9, KLK10, KLK11, KLK12, KLK13, KLK14, and KLK15.
[0013] Further preferably, the first specific protease is selected from KLK5 enzyme
[0014] Further preferably, the Caspase protease is selected from Caspase-14 enzyme.
[0015] Further preferably, the cleaved toxin is also cleaved by a second specific protease.
[0016] The second specific protease also includes non-human enterokinase, tobacco etch virus protease (TEV enzyme), a protease derived from Bacillus subtilus, a protease derived from Bacillus amyliquifaciens, a protease derived from a rhinovirus, papain, a homolog of insect papain, or a homolog of crustacean papain.
[0017] Further preferably, the second specific protease further comprises TEV enzyme.
[0018] Further preferably, the substrate protein contains an enzyme cleavage site that can be specifically cleaved by the enzyme cleavage toxin.
[0019] More preferably, the restriction site is derived from SNARE protein.
[0020] More preferably, the restriction site is derived from SNAP25 protein.
[0021] More preferably, the substrate protein is also fused with a fluorescent protein.
[0022] Further preferably, the restriction site is selected from SNAP25(naa), wherein aa refers to amino acid and n refers to the number of amino acids.
[0023] Further preferably, the SNAP25(naa) is selected from SNAP25(17aa) or SNAP25(66aa).
[0024] More preferably, the enzyme cleavage sequence of SNAP25 is positions 187-203 of its amino acid sequence.
[0025] More preferably, the enzyme cleavage sequence of SNAP25 is positions 141-206 of its amino acid sequence.
[0026] Further preferably, the SNAP25 (17aa) protein has the enzyme cleavage sequence described in SEQ ID NO: 24, or is a polypeptide having ≥85%, ≥90%, ≥95%, ≥97%, ≥98% or ≥99% homology with the amino acid sequence shown in SEQ ID NO: 24, and having the same activity as the sequence of SEQ ID NO: 24.
[0027] Further preferably, the SNAP25 (66aa) protein has the enzyme cleavage sequence described in SEQ ID NO: 25, or is a polypeptide having ≥85%, ≥90%, ≥95%, ≥97%, ≥98% or ≥99% homology with the amino acid sequence shown in SEQ ID NO: 25, and having the same activity as the sequence of SEQ ID NO: 25.
[0028] Further preferably, the fluorescent protein is selected from cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), green fluorescent protein (GFP), red fluorescent protein (RFP), orange fluorescent protein (OFP) or blue fluorescent protein (BFP).
[0029] More preferably, the fluorescent protein is selected from two or more types.
[0030] Further preferably, the substrate protein is selected from FP1-SNAP25(naa)-FP2, wherein FP1 and FP2 both refer to the above-mentioned fluorescent proteins, and FP1 and FP2 are different.
[0031] Further preferably, the FP1 is a cyan fluorescent protein, and the FP2 is a yellow fluorescent protein.
[0032] Further preferably, the substrate protein is selected from CFP-SNAP25(naa)-YFP.
[0033] Further preferably, the sequence of the CFP is SEQ ID NO: 27, or a polypeptide having ≥85%, ≥90%, ≥95%, ≥97%, ≥98% or ≥99% homology with the amino acid sequence shown in SEQ ID NO: 27 and having the same activity as the sequence of SEQ ID NO: 27.
[0034] Further preferably, the sequence of the YFP is SEQ ID NO: 28, or a polypeptide having ≥85%, ≥90%, ≥95%, ≥97%, ≥98% or ≥99% homology with the amino acid sequence of SEQ ID NO: 28 and having the same activity as the sequence of SEQ ID NO: 28.
[0035] Further preferably, the sequence of the substrate protein is SEQ ID NO:29 or SEQ ID NO:30, or a polypeptide having ≥85%, ≥90%, ≥95%, ≥97%, ≥98% or ≥99% homology with the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30, and having the same activity as the sequence of SEQ ID NO::29 or SEQ ID NO:30.
[0036] Further preferably, the system also has a combination of any one or more of the following features: the concentration of HEPES is 0-1M, the concentration of NaCl is 0-100mM, the concentration of DTT is 0-10mM, the volume concentration of Tween is 0-1%, the volume concentration of Zn(OAc) is 0-10%, and the volume concentration of Zn(OAc) is 0-10%. 2 The concentration is 0-1 mM, the concentration of the substrate protein is 1-2 mg / ml, and the concentration of the enzyme-cleaved toxin is 1-500 μg / ml.
[0037] Further preferably, the system also has a combination of any one or more of the following features: the concentration of HEPES is 10-200 mM, the concentration of NaCl is 1-10 mM, the concentration of DTT is 0-5 mM, the volume concentration of Tween is 0.01-0.5%, the Zn(OAc) 2 The concentration is 0.1-0.5 mM, the concentration of the substrate protein is 0.1-2 mg / ml, and the concentration of the active botulinum toxin is 10-200 μg / ml.
[0038] Further preferably, the system also has a combination of any one or more of the following features: the concentration of HEPES is 50-100 mM, the concentration of NaCl is 1-5 mM, the concentration of DTT is 0.5-2 mM, the volume concentration of Tween is 0.01-0.1%, the Zn(OAc) 2 The concentration is 0.1-0.2 mM, the concentration of the substrate protein is 0.1-0.8 mg / ml, and the concentration of the active botulinum toxin is 10-140 μg / ml.
[0039] The second aspect of the present invention provides a method for detecting toxin activity, using the system described in the first aspect of the present invention and performing detection by a fluorescence test method.
[0040] Further preferably, the fluorescence testing method adopts the fluorescence resonance energy transfer (FRET) method.
[0041] More preferably, the assay method further comprises: (1) using an enzyme to digest the toxin to be detected to obtain the digested toxin; (2) preparing a reaction system, wherein the reaction system comprises HEPES, NaCl, DTT, Tween or Zn(OAc) 2 one or more of the above, the enzyme-cleaved toxin described in step (1), and the substrate protein; (3) mixing the reaction system described in step (2) evenly, adding it to an ELISA plate and performing on-machine detection; (4) after the on-machine detection is completed, adding Trypsin to terminate the reaction, performing on-machine reading, and calculating the enzyme activity of the toxin based on the ratio of different fluorescence values.
[0042] Further preferably, the buffer is alkaline.
[0043] More preferably, the pH value of the buffer solution is 7.0 to 8.0; more preferably, the pH value is 7.0 to 7.5; and most preferably, the pH value is 7.4.
[0044] More preferably, the concentration of the enzyme is 0.1-10 μg / ml; more preferably, the concentration of the enzyme is 1-5 μg / ml; most preferably, the concentration of the enzyme is 1.4-2 μg / ml.
[0045] More preferably, the volume concentration of Trypsin is 0.01% to 5%; more preferably 0.1% to 2%; most preferably 0.25% to 1%.
[0046] Further preferably, the structure of the botulinum toxin is SP-8His-F2-LC-D(QTQS-F1)-HC-F2-EGFP-8His (Formula 1), connected from the N-terminus to the C-terminus;
[0047] In Formula 1, D represents the middle amino acid sequence region, KTKS is a part of the natural type A botulinum toxin cleavage site, and F1 represents the first enzyme cleavage site designed by the present invention, which respectively correspond to several different first proteases, KLK5, KLK7, SASPase, and Caspase-14;
[0048] F2 is the second enzyme cleavage site, corresponding to the second protease, and the second protease in this embodiment is TEV enzyme;
[0049] SP is a signal peptide (SEQ ID NO: 9), 8His is a tag protein (HHHHHHHH); EGFP (SEQ ID NO: 31), a fluorescent protein, is used for quantification;
[0050] LC is the first domain. In this embodiment, the amino acid sequence of LC is SEQ ID NO: 10:; HC is the second domain. In this embodiment, the amino acid sequence of HC is SEQ ID NO: 17;
[0051] The lysine 423 of HC was mutated to asparagine.
[0052] The beneficial effect of the present invention is that the toxin (such as botulinum toxin type A) is enzymatically cleaved. In the system described in the present invention, the fluorescence resonance energy transfer (FRET) method is used to make the enzyme activity determination of special structural toxins more convenient, and high-throughput determination of the enzyme activity of the toxin can be achieved, and the determination is more efficient and accurate. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] Figure 1 The fluorescence resonance energy transfer (FRET) system was demonstrated, and when there was an excitation light at a wavelength of 433 nm, a fluorescence signal could be received at a wavelength of 526 nm after passing through the FP1-SNAP25(naa)-FP2 system.
[0054] Figure 2 It was demonstrated that when double-enzyme-cutting botulinum toxin type A was added, botulinum toxin type A functioned to cut the FP1-SNAP25(naa)-FP2 substrate, destroying its FP1-SNAP25(naa)-FP2 system. At this time, when excited with 433nm excitation light, a fluorescence signal could be received at a wavelength of 476nm, while the fluorescence signal at a wavelength of 526nm weakened with the enzyme cleavage reaction.
[0055] Figure 3 This is a general diagram of the comparison of conversion rates of different substrate concentrations in Example 2.
[0056] Figure 4The conversion rate comparison of CFP-SNAP25 (17aa) -YFP substrate protein and CFP-SNAP25 (66aa) -YFP substrate protein at different concentrations in Example 2 is shown in FIG.
[0057] Figure 5 is the substrate conversion rate of substrate protein CFP-SNAP25(17aa)-YFP and substrate protein CFP-SNAP25(66aa)-YFP at different concentrations in Example 2
[0058] Figure 6 The conversion rates of substrate protein CFP-SNAP25(17aa)-YFP at different concentrations in Example 2 show a linear relationship within a certain period of time.
[0059] Figure 7 This is a comparison chart of the conversion rate of single-enzyme-cleaved botulinum toxin type A and double-enzyme-cleaved botulinum toxin type A.
[0060] Figure 8 Comparison of the conversion rate of double-enzyme-cleaved botulinum toxin type A substrate protein, indicating that the conversion rate of double-enzyme-cleaved botulinum toxin type A substrate protein presents a linear relationship within a certain period of time
[0061] Fig. 9 Comparison of conversion rates of single enzyme-cleaved botulinum toxin type A substrates
[0062] Fig.10 This is a comparison of the substrate protein conversion rates of KLK5 enzyme and double-enzyme-cleaved botulinum toxin type A, where NE refers to double-enzyme-cleaved botulinum toxin type A, indicating that the substrate protein conversion rates of double-enzyme-cleaved botulinum toxin type A and KLK5 enzyme show a linear relationship within a certain period of time.
[0063] Fig.11 Comparison of the conversion rate of KLK5-cleaved substrate proteins
[0064] Fig.12 The comparison of the conversion rate of double-enzyme-digested botulinum toxin type A substrate protein shows that it is linear within a certain period of time.
[0065] Fig.13 Comparison of the conversion rate of KLK5-cleaved substrate proteins
[0066] Fig.14 Comparison of substrate protein conversion rate after adding BSA and PMSF to the enzyme digestion reaction system
[0067] Fig.15 Comparison of substrate protein conversion rate after adding high zinc ion concentration to the enzyme digestion reaction system
[0068] Fig.16When pH=5, the conversion rates of substrate protein by double-digestion botulinum toxin type A and KLK5 enzyme in the enzyme digestion system at the same DTT concentration are compared, where E represents double-digestion botulinum toxin type A, and the number after DDT represents the concentration of DDT.
[0069] Fig.17 The figure is a comparison of the conversion rate of substrate protein by double-digestion botulinum toxin type A and KLK5 enzyme in the enzyme digestion system with the same DTT concentration. E represents double-digestion botulinum toxin type A, Neg represents KLK5 enzyme, and the number after DDT represents the concentration of DDT. Fig.17 Related definitions and diagrams Fig.18 and Fig.19 same.
[0070] Fig.18 Comparison of the conversion rates of substrate protein by double-digestion botulinum toxin type A and KLK5 enzyme in enzyme cleavage systems (containing Tween80) with different DTT concentrations.
[0071] Fig.19 The figure in the middle shows the effect of the double-enzyme cleavage toxin on the enzymatic cleavage of the substrate in the enzymatic cleavage system with different concentrations of Tween80.
[0072] Fig. 20 Comparison of substrate conversion rates for KLK5 enzyme, double-digested botulinum toxin 150 and five tested single-digested botulinum toxins DETAILED DESCRIPTION
[0073] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application may be combined with each other.
[0074] The present invention is further described below in conjunction with specific embodiments and examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are preferably followed or referred to the conditions indicated in the specific embodiments described above, and then can be followed according to conventional conditions or according to the conditions recommended by the manufacturer.
[0075] Unless otherwise specified, the percentages and parts mentioned in the present invention are percentages and parts by weight.
[0076] Unless otherwise specified, the materials and reagents used in the examples of the present invention are all commercially available products.
[0077] Unless otherwise specified, the temperature units in this application are all degrees Celsius (°C).
[0078] Nouns and terms
[0079] The following is an explanation or description of the meaning of some relevant "nouns" and "terms" used in the present invention, so as to better understand the present invention. The corresponding explanation or description applies to the full text of the present invention, both below and above. When the present invention involves references, the definitions of relevant terms, nouns, and phrases in the references are also quoted, but when they conflict with the definitions in the present invention, the definitions in the present invention shall prevail. When the definitions in the references conflict with the definitions in the present invention, it does not affect the cited components, substances, compositions, materials, systems, formulations, types, methods, equipment, etc., which shall be subject to the contents determined in the references.
[0080] In the present invention, preferred embodiments such as “preferred”, “better”, “more preferred”, “better”, “most preferred” and “further preferred” do not constitute any limitation on the scope of coverage and protection scope of the invention, and are not used to limit the scope and embodiments of the present invention, but are only used to provide some embodiments as examples.
[0081] In the description of the present invention, preferred modes such as "one of the preferred embodiments", "one of the preferred modes", "one of the preferred embodiments", "one of the preferred examples", "preferred examples", "in a preferred embodiment", "some preferred examples", "some preferred modes", "preferably", "preferably", "preferably", "more preferably", "more preferably", "further preferably", "most preferably", and illustrative enumeration modes such as "one of the embodiments", "one of the modes", "example", "specific example", "for example", "as an example", "for example", "such as", "such as", etc., do not constitute any limitation on the scope of coverage and protection scope of the invention, and the specific features described in each mode are included in at least one specific embodiment of the present invention. In the present invention, the specific features described in each mode may be combined in a suitable manner in any one or more specific embodiments. In the present invention, the technical features or technical solutions corresponding to each preferred mode may also be combined in any suitable manner.
[0082] In the present invention, "any combination thereof" means "greater than 1" in terms of quantity, and means a group consisting of the following situations in terms of coverage: "select any one of them, or select a group consisting of at least two of them".
[0083] In the present invention, the descriptions of "one or more", "one or more" and "one or more" have the same meaning as "at least one", "at least one", "a combination thereof", "or a combination thereof", "and combinations thereof", "or any combination thereof", "and any combination thereof", etc. and can be used interchangeably to indicate that the quantity is equal to "1" or "greater than 1".
[0084] In the present invention, "or / and" and "and / or" are used to represent "optionally one of them or optionally a combination of them", and also represent at least one of them.
[0085] The term "about" can refer to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. For example, as used herein, the expression "about 100" includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0086] Sequence identity (or homology) is determined by comparing two aligned sequences along a predetermined comparison window (which can be 50%, 60%, 70%, 80%, 90%, 95% or 100% of the length of the reference nucleotide sequence or protein) and determining the number of positions at which identical residues occur. Typically, this is expressed as a percentage. The measurement of sequence identity of nucleotide sequences is a method well known to those skilled in the art.
[0087] The prior art means described in the present invention in such ways as “usually”, “conventional”, “general”, “frequently” and “often” are also cited as references to the contents of the present invention. Unless otherwise specified, they can be regarded as one of the preferred ways of some technical features of the present invention. It should be noted that they do not constitute any limitation on the scope of coverage and protection scope of the invention.
[0088] All documents mentioned in the present invention and documents directly or indirectly cited by these documents are cited in this application as references, just as if each document was cited individually as a reference.
[0089] The "mutation" mentioned in the present invention includes insertion, deletion and substitution of amino acids.
[0090] In vitro protein synthesis reaction refers to the reaction of synthesizing protein in an in vitro cell-free synthesis system, including at least the translation process. Including but not limited to IVT reaction (in vitro translation reaction), IVTT reaction (in vitro transcription and translation reaction), IVDTT reaction (in vitro replication transcription and translation reaction). In the present invention, IVTT reaction is preferred. IVTT reaction, corresponding to IVTT system, is the process of transcribing and translating DNA into protein (Protein) in vitro. Therefore, we also refer to this type of in vitro protein synthesis system as D2P system, D-to-P system, D_to_P system, DNA-to-Protein system; the corresponding in vitro protein synthesis method is also called D2P method, D-to-P method, D_to_P method, DNA-to-Protein method.
[0091] "Cell-free system" refers to a method of in vitro protein synthesis that is not secretory expression through intact cells. It should be noted that in the in vitro cell-free protein synthesis system of the present invention, it is also allowed to add cell components to promote the reaction, but the added cells are not primarily intended to secrete and express exogenous target proteins. In addition, in the intact cell-free D2P system constructed under the guidance of the present invention, a small amount of intact cells are intentionally added (for example, the protein content provided by them is not more than 30wt% compared to the protein content provided by the cell extract). Such a "circumvention" method is also included in the scope of protection of the present invention.
[0092] Target protein: The target expression product of the in vitro protein synthesis system of the present invention is not synthesized by host cell secretion, but is synthesized in vitro based on an exogenous nucleic acid template, and may also be referred to as an exogenous protein. The exogenous protein may be a protein, a fusion protein, a mixture of protein molecules or fusion protein molecules; it also broadly includes polypeptides. The product obtained after an in vitro protein synthesis reaction based on a nucleic acid template encoding the target protein may be a single substance or a combination of two or more substances. "Exogenous protein", "target protein", "target protein", "target translation product" have the same meaning and can be translated as "objective protein", "interested protein", "objective translated product", "interested protein product", etc., and may be used interchangeably in the present invention.
[0093] D2P, DNA-to-Protein, from DNA template to protein product. For example, D2P technology, D2P system, D2P method, D2P kit, etc.
[0094] "The expression system of the present invention", "the in vitro expression system of the present invention", "the in vitro cell-free expression system", and "the in vitro cell-free expression system" can be used interchangeably, all referring to the in vitro protein expression system of the present invention, and other descriptions can also be used, such as: protein in vitro synthesis system, in vitro protein synthesis system, cell-free system, cell-free system, cell-free protein synthesis system, cell-free in vitro protein synthesis system, in vitro cell-free protein synthesis system, in vitro cell-free synthesis system, CFS system (cell-free system), CFPS system (cell-free protein synthesis system) and other descriptions. According to the reaction mechanism, it can include an in vitro translation system (which can be abbreviated as an IVT system, a mR2P system), an in vitro transcription translation system (which can be abbreviated as an IVTT system, a D2P system), an in vitro replication transcription translation system (which can be abbreviated as an IVDTT system, a D2P system), etc. In the present invention, the IVTT system is preferred. We also call the in vitro protein synthesis system a "protein synthesis factory" ("Protein Factory" or "proteinfactory" or "Proteinfactory"). The in vitro protein synthesis system provided by the present invention adopts an open description method for its components. The cell-free protein synthesis system of the present invention uses exogenous DNA, mRNA or a combination thereof as a nucleic acid template for protein synthesis, and achieves in vitro synthesis of the target protein by artificially controlling the addition of substrates and transcription, translation-related protein factors and other substances required for protein synthesis.
[0095] In the in vitro synthesis reaction of the embodiments of the present invention, the cell-free in vitro synthesis system, template, plasmid, target protein, in vitro synthesis reaction (incubation reaction), various preparation methods, various detection methods and other technical elements can also be independently selected from the following documents. Suitable implementation methods or implementation methods include but are not limited to CN111484998A, CN106978349A, CN108535489A, CN108690139A, CN108949801A, CN108642076A, CN109022478A, CN109423496A, C N109423497A, CN109423509A, CN109837293A, CN109971783A, CN109988801A, CN109971775A, CN110093284A, CN110408635A, CN110408636A, CN110551745A, CN110551700A, CN110551785A, CN110819647A, CN110845622A, CN110938649A, CN110964736A, etc. Unless otherwise in conflict with the purpose of the present invention, these documents and their citations are cited in their entirety and for all purposes.
[0096] In the present invention, "protein" and "protein" have the same meaning, are both translated as protein, and can be used interchangeably.
[0097] In the present invention, "system" and "system" are both translated as system and can be used interchangeably.
[0098] In the present invention, "protein synthesis amount", "protein expression amount" and "protein expression yield" have the same meaning and can be used interchangeably.
[0099] In the present invention, cell extract, cell extract, cell lysate, cell disruption product and cell lysate have the same meaning and can be used interchangeably. In English, cell extract, cell lysate and the like can be used.
[0100] In the present invention, the cell is selected from bacteria, mammalian cells, human cells, plant cells, yeast cells, insect cells or any combination thereof; preferably yeast cells.
[0101] In the present invention, energy system, energy system, and energy supply system have the same meaning and can be used interchangeably. Energy regeneration system and energy regeneration system have the same meaning and can be used interchangeably. The energy regeneration system is a preferred embodiment or component of the energy system.
[0102] Furthermore, the present invention provides a cell-free protein synthesis system, which at least includes a cell extract or a cell lysate.
[0103] Further preferably, the cell-free protein synthesis system further comprises one or more components selected from the following group: a substrate for synthesizing RNA, a substrate for synthesizing protein, polyethylene glycol or its analogues, magnesium ions, potassium ions, a buffer, RNA polymerase, an energy regeneration system, dithiothreitol, and an optional aqueous solvent.
[0104] Further preferably, the substrate for synthesizing RNA includes: nucleoside monophosphate, nucleoside triphosphate or a combination thereof.
[0105] Further preferably, the substrate for synthesizing protein includes: 20 natural amino acids and unnatural amino acids.
[0106] Further preferably, the magnesium ions are derived from a magnesium ion source, and the magnesium ion source is selected from the following group: magnesium acetate, magnesium glutamate, or a combination thereof.
[0107] Further preferably, the potassium ions are derived from a potassium ion source, and the potassium ion source is selected from the following group: potassium acetate, potassium glutamate, or a combination thereof.
[0108] Further preferably, the energy regeneration system is selected from the following group: one or a combination of creatine phosphate / creatine phosphate enzyme system, glycolysis pathway and its intermediate energy system.
[0109] Further preferably, the energy regeneration system comprises a glucose / phosphate system, and the phosphate is selected from the following group: tripotassium phosphate, triammonium phosphate, trisodium phosphate, dipotassium hydrogen phosphate, diammonium hydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, ammonium dihydrogen phosphate, sodium dihydrogen phosphate, or a combination thereof.
[0110] Further preferably, the buffer is selected from the following group: 4-hydroxyethylpiperazineethanesulfonic acid, tris(hydroxymethyl)aminomethane, or a combination thereof.
[0111] Further preferably, the in vitro protein synthesis system contains polyethylene glycol (PEG) or its analogs. The concentration of polyethylene glycol or its analogs is not particularly limited. Generally, the concentration (w / v) of polyethylene glycol or its analogs is 0.1-8%, preferably 0.5-4%, more preferably 1-2%, based on the total weight of the protein synthesis system. Representative PEG is selected from the following group: one of PEG3000, PEG3350, PEG6000, PEG8000 or a combination thereof.
[0112] Further preferably, the polyethylene glycol includes polyethylene glycol with a molecular weight (Da) of 200-10000, such as PEG200, 400, 1500, 2000, 4000, 6000, 8000, 10000, etc., preferably, polyethylene glycol with a molecular weight of 3000-10000.
[0113] In the present invention, the RNA polymerase is not particularly limited and can be selected from one or more RNA polymerases, and a typical RNA polymerase is T7 RNA polymerase.
[0114] An optional scheme is that the in vitro protein synthesis system provided by the present invention includes: cell extract, 4-hydroxyethylpiperazineethanesulfonic acid, potassium acetate, magnesium acetate, adenosine triphosphate (ATP), guanosine triphosphate (GTP), cytosine triphosphate (CTP), thymidine triphosphate (TTP), amino acid mixture, creatine phosphate, dithiothreitol (DTT), creatine phosphate kinase, and RNA polymerase.
[0115] In the present invention, the cell extract does not contain intact cells, and a typical cell extract includes ribosomes, aminoacyl-tRNA synthetases, initiation factors and elongation factors required for protein synthesis, and termination release factors for protein translation. In addition, the cell extract also contains some other proteins derived from the cytoplasm of the cell, especially soluble proteins.
[0116] In the present invention, the proportion of the cell extract in the in vitro cell-free protein synthesis system is not particularly limited. Usually, the cell extract accounts for 20-70% of the in vitro cell-free protein synthesis system, preferably 30-60%, and more preferably 40-50%.
[0117] In the present invention, the protein content of the cell extract is 20-100 mg / mL, preferably 50-100 mg / mL. The method for determining the protein content is the Coomassie Brilliant Blue determination method.
[0118] The present invention also provides a vector or vector combination, wherein the vector contains the nucleic acid construct of the present invention. Preferably, the vector is selected from: bacterial plasmid, bacteriophage, yeast plasmid, animal cell vector, shuttle vector; the vector is a transposon vector. Methods for preparing recombinant vectors are well known to those of ordinary skill in the art. As long as they can replicate and be stable in the host, any plasmid and vector can be used.
[0119] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (including but not limited to the embodiments) can be combined with each other to form a new or preferred technical solution, as long as it can be used to implement the present invention. Due to space limitations, they will not be described one by one.
[0120] The present invention is to detect toxins with the following structures:
[0121] The toxin provided by the present invention is a single-chain polypeptide, comprising: a first domain, an intermediate amino acid sequence region, and a second domain, wherein the intermediate amino acid sequence region is between the first domain and the second domain, and the intermediate amino acid sequence region sequence contains at least one first enzyme cleavage site, and the first enzyme cleavage site is designed to be highly specifically cleaved by a first protease present in a specific part of the human body. After the single-chain polypeptide is cleaved by the first protease at the first enzyme cleavage site, it is converted into an activated form that can inhibit the release of information substance.
[0122] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first domain has a molecular weight of about 50 kDa, the second domain has a molecular weight of about 100 kD, and the first domain has cleavage activity.
[0123] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the information substance is an intercellular information substance, preferably any one of a neurotransmitter, an endocrine hormone, a local chemical mediator and a gas signal molecule, and more preferably the information substance is acetylcholine.
[0124] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first domain is a non-toxic cell protease or a fragment thereof that can cut the protein of the exocytosis fusion apparatus of the target cell; the second domain has a binding portion and a transport portion, the binding portion can bind to the target cell receptor and enter the endosome of the target cell through receptor-mediated endocytosis, and the transport portion can transport the first domain into the cytosol of the target cell;
[0125] Preferably, the first cleavage site is between the first domain and the transport portion, and / or the binding portion is a carboxyl terminal with a molecular weight of about 50 kD, and the transport portion is an amino terminal with a molecular weight of about 50 kD;
[0126] Another preferred embodiment is that the protein of the exocytosis fusion apparatus is the neuronal snare protein, and / or the target binding site is a receptor on the presynaptic membrane of the neuron.
[0127] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first domain at least includes a part of the L chain of the Clostridium neurotoxin:
[0128] Preferably, the portion of the Clostridium neurotoxin L chain is a neurotoxin L chain of one of Clostridium botulinum subtypes A, B, C, D, E and F or is derived therefrom, and / or the first domain contains an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to SEQ ID NOs: 10 to 16, or contains an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of 11-16 except for a naturally occurring enzyme cleavage sequence; and / or
[0129] The second domain comprises at least a portion of a Clostridium neurotoxin H chain, preferably a portion of the Clostridium neurotoxin H chain is a neurotoxin heavy chain of one of the following: Clostridium botulinum subtype A, Clostridium botulinum subtype B, Clostridium botulinum subtype C, Clostridium botulinum subtype D, Clostridium botulinum subtype E, Clostridium botulinum subtype F, Clostridium botulinum subtype G, Clostridium baratii and Clostridium butyricum; or a portion of the Clostridium neurotoxin H chain is a neurotoxin H chain of Clostridium tetani or is derived therefrom, and / or
[0130] The second domain comprises an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 17-23.
[0131] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the number of amino acids in the linker (L1) between the first domain and the intermediate amino acid sequence region is 0-20 or 0-10 amino acids or 0-5; and / or the number of amino acids in the linker (L2) between the intermediate amino acid sequence region and the second domain is 0-20 or 0-10 amino acids or 0-5.
[0132] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first protease is not a protease existing in the human digestive tract,
[0133] Preferably, the specific part of the human body is human skin tissue, and / or at least one of the first proteases is selected from the following:
[0134] Any one or more of epidermal specific kallikrein (KLKs) proteases (e.g., KLK5, KLK6, KLK7), SASPase proteases, Caspase proteases (e.g., Caspase-14), Furin proteases, and their respective variants retaining enzymatic activity; and / or,
[0135] The first enzyme cleavage site is selected from YRSRIV (KLK5 cleavage site), KHLYSN (KLK7 cleavage site), VSQVYPIVQ (SASPase cleavage site), WEHDGIAE (Caspase-14 cleavage site), RXXR (Furin protease cleavage site) or RRXX (Furin protease cleavage site) or has an amino acid sequence that is at least 50%, 60%, 85%, 90%, 99% or 100% identical to any of the above.
[0136] Wherein, "X" in RXXR and RRXX is any amino acid, preferably, XX in RXXR is RK, TK or TR; and "XX" in RRXX is SV or KR.
[0137] The single-chain polypeptide provided by the present invention also has such a feature, and further comprises: any one or more of a signal peptide for increasing the expression amount, a quantitative protein for quantification, and a tag protein, and further, one or more of the signal peptide, the quantitative protein, and the tag protein are respectively defined as follows: the signal peptide contains an amino acid sequence that is at least 80%, 85%, 90%, 99% or 100% identical to SEQ ID NO: 9; the quantitative protein is a fluorescent protein;
[0138] The tag protein is one or more of a His tag, a GST tag, an MBP tag and a Strep-tagII tag.
[0139] The single-chain polypeptide provided by the present invention also has the following characteristics, and further comprises: two second enzyme cleavage sites respectively located at the N-terminus of the first domain and the C-terminus of the second domain, and the second protease that cleaves the second enzyme cleavage site cannot cleave the first enzyme cleavage site.
[0140] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein, the first enzyme cleavage site and / or the second enzyme cleavage site are usually not cleaved by the protease contacted during the expression of the single-chain polypeptide in the host cell in vivo or the synthesis of the single-chain polypeptide by an in vitro synthesis system involving cell extracts from host cells.
[0141] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the second enzyme cleavage site is designed to be highly specific to the second protease, preferably, the second protease is selected from non-human enterokinase, tobacco etch virus protease, protease derived from Bacillus subtilus, protease derived from Bacillus amyliquifaciens, protease derived from rhinovirus, papain, homologues of insect papain or homologues of crustacean papain; and / or
[0142] The sequence of the second enzyme cleavage site is DDDK, ENLYFQS, HY, YH or LEVLFQGP, or has an amino acid sequence that is at least 85%, 90%, 99% or 100% identical to any of the above sequences.
[0143] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the intermediate amino acid sequence region sequence further includes XTXS, wherein X is not a K amino acid, preferably: X is a Q amino acid; and / or
[0144] The structure of the intermediate amino acid sequence region sequence from N-terminus to C-terminus is:
[0145] XTXS-linker (L3) - at least one first enzyme cleavage site, further, the number of amino acids in L3 is 0-20 or 0-10 or 0-5, and further, the first enzyme cleavage site is 1.
[0146] The single-chain polypeptide provided by the present invention also has the following characteristics: when the second domain contains an amino acid sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 17, the lysine at the position corresponding to the 423rd position of the amino acid sequence of the second domain is mutated to a non-lysine.
[0147] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein, the first domain, the middle amino acid sequence region and the second domain are connected from the N-terminus to the C-terminus; and / or when there are multiple first restriction enzyme cleavage sites, multiple first restriction enzyme cleavage sites are sequentially connected from the N-terminus to the C-terminus, all of the first restriction enzyme cleavage sites have the same restriction enzyme cleavage site or each first restriction enzyme cleavage site is different, and the number of amino acids in the linker (L4) between the multiple restriction enzyme cleavage sites is 0-20 or 0-10 amino acids or 0-5.
[0148] Toxins with this structure need to be cleaved by the first specific protease to convert them into an active form before their activity can be tested in vitro. Only then can the substrate protein be tested, allowing for in vitro activity testing.
[0149] The present invention takes botulinum toxin type A as an example. In order to simply, efficiently and accurately detect the enzymatic activity of botulinum toxin type A, the present invention adopts the fluorescence resonance energy transfer (FRET) method, that is, when the donor and the acceptor are very close to each other (1-10nm), the photon energy is transferred from one excited fluorophore (donor) to another fluorophore (acceptor). The present invention adopts the CFP-SNAP25 (naa) -YFP system. When excited with 433nm excitation light in the normal state, the emission light signal can be received at 527nm (yellow light). When active botulinum toxin type A is present, because the CFP-SNAP25 (naa) -YFP system is cut by botulinum toxin type A, when excited with 433nm excitation light, the emission light signal will be received at 476nm (blue light). At this time, the activity of botulinum toxin type A cleavage substrate can be calculated by the change in the ratio of blue light to yellow light (see Figure 1 and Figure 2 ).
[0150] In the following examples, for the enzyme-cleaved toxins to be detected, double enzyme cleavage refers to enzyme cleavage using a first specific protease and a second specific protease respectively; single enzyme cleavage refers to enzyme cleavage using only the second specific protease.
[0151] Example 1: Preparation of botulinum toxin type A
[0152] 1. Construction of target plasmid:
[0153] (1) Constructing a target plasmid containing a nucleotide sequence encoding a protein structure as shown in Formula 1:
[0154] SP-8His-F2-LC-D(QTQS-F1)-HC-F2-EGFP-8His (Formula 1), N-terminal to C-terminal connection;
[0155] In Formula 1, D represents the middle amino acid sequence region, QTQS is a part of the type A botulinum toxin cleavage site, and F1 represents the first enzyme cleavage site designed by the present invention, which respectively correspond to several different first proteases, including KLK5, KLK7, SASPase, and Caspase-14;
[0156] Preferably, the sequence of the KLK5 cleavage site is YRSRIV; the sequence of the KLK7 cleavage site is KHLYSN; the sequence of the SASPase cleavage site is VSQVYPIVQ; and the sequence of the Caspase-14 cleavage site is WEHDGIAE.
[0157] F2 is the second enzyme cleavage site, corresponding to the second protease, and the second protease in this embodiment is TEV enzyme;
[0158] Preferably, the sequence of the TEV enzyme cleavage site is ENLYFQS.
[0159] SP is a signal peptide (SEQ ID NO: 9), 8His is a tag protein (HHHHHHHH); EGFP (SEQ ID NO: 31) is a fluorescent protein, used for quantification
[0160] LC is the first domain. In this embodiment, the amino acid sequence of LC is SEQ ID NO: 10; HC is the second domain. In this embodiment, the amino acid sequence of HC is SEQ ID NO: 17;
[0161] Starting from LC, the lysine at positions 438 and 440 were mutated into alanine to construct the corresponding transformed target plasmid, that is, the middle amino acid sequence region D was QTQS-F1.
[0162] The lysine 423 of HC was mutated to asparagine.
[0163] The primers in Table 1 correspond to the nucleotide sequences encoding the above protein structures corresponding to different first proteases;
[0164] According to each primer pair in Table 1, the correct sequence was obtained by the QuickChange PCR method, and different target plasmids were obtained by transformation.
[0165]
[0166] (3) Plasmid transformation
[0167] Transformation of each target plasmid was performed as follows:
[0168] Add 1 μl of target plasmid to 20 μl of DH5α, place on ice for 30 min, heat shock at 42°C for 45 s, place on ice for 2 min, add 500 μl of culture medium, and culture at 37°C with shaking for 1 h (200 rpm). Pipette 100 μl onto LB (containing antibody) plate, culture at 37°C inverted for 12-16 h, and store in a 4°C refrigerator.
[0169] (4) Extract and amplify the transformed plasmid:
[0170] Amplification system: random primers with a final concentration of 20-30 μM, 0.05-0.15 μg / mL plasmid template, 0.5-1 mM dNTP, 2×BSA, 1×phi29 reaction buffer (components: 50 mM Tris-HCl, 10 mM MgCl2, 10 mM (NH4)2SO4, 4 mM DTT, pH7.5);
[0171] Take 10ml amplification system as an example:
[0172] Mix 10 ml of the amplification system, a plasmid with a final concentration of 4 ng / μl, and 5 μl of 0.05-0.1 mg / mL phi29 DNA polymerase, react at 37°C and 30 rpm for 2 hours, and then identify by electrophoresis using 1% agarose gel.
[0173] 2. In vitro cell-free protein synthesis (IVTT)
[0174] In vitro cell-free protein synthesis system: 22 mM 4-hydroxyethylpiperazineethanesulfonic acid at a final concentration of pH 7.4, 30-150 mM potassium acetate, 1.0-5.0 mM magnesium acetate, 1.5-4 mM nucleoside triphosphate mixture (adenosine triphosphate, guanosine triphosphate, cytosine triphosphate and uridine triphosphate), 0.08-0.24 mM amino acid mixture (glycine, alanine, valine, leucine, isoleucine, phenylalanine, proline, tryptophan, serine, tyrosine, cysteine, methionine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine and histidine), 25 mM creatine phosphate, 1.7 mM dithiothreitol, 0.27 mg / mL creatine phosphate kinase, 0.027-0.054 mg / mL T7 RNA polymerase, 1%-4% polyethylene glycol, 0.5%-2% sucrose, and finally 50-80% volume of yeast cell extract are added.
[0175] The yeast cell extract of this example is from Kluyveromyces lactis.
[0176] More specifically, the IVTT reaction was performed using the Standard product from the protein factory of Kangma (Shanghai) Biotechnology Co., Ltd.:
[0177] The amplified product (DNA template) obtained in Example 1 was added to the cell-free in vitro protein synthesis system at a volume ratio of 1:30 to the in vitro cell-free protein system, and reacted at 100 rpm in a constant temperature box at 30±2 degrees for 3 to 6 hours.
[0178] 3. Purify the protein synthesized in vitro: Purify according to the following steps:
[0179] (1) Determine the amount of magnetic beads: The amount of magnetic beads is 1% of the amount used in the in vitro cell-free protein synthesis system.
[0180] (2) Magnetic bead cleaning: Wash three times with water before use, vortex for 15 seconds each time, and collect the magnetic beads using a magnetic rack. The amount of water used each time should be 5-10 times the amount of magnetic beads.
[0181] (3) Binding of target protein to magnetic beads: Mix the washed magnetic beads and IVTT product in a large beaker, allow to bind at 4°C, 100 rpm for 1 hour, and collect the magnetic beads into a centrifuge tube.
[0182] (4) Washing: Wash the protein-loaded magnetic beads three times with 30 mM imidazole at 180 rpm for 10 min each time. The amount of washing solution used should be 3-5 times the volume of the magnetic beads.
[0183] (5) Elute with 280 mM imidazole eluent: the amount of eluent used is twice the amount of magnetic beads used.
[0184] (6) Centrifugal separation: Centrifuge to remove residual magnetic beads, first time for 5 minutes, 12000rpm:
[0185] Among them, the elution of (4)-(5) was carried out under the condition of pH 8.0.
[0186] The following examples are verified using the toxin in which F1 is the KLK5 cleavage site as an example.
[0187] Example 2
[0188] 1. At 20-30°C, digest botulinum toxin type A with KLK5 enzyme for at least 8 hours, then add 3mM GSH, 0.3mM GSSSG, and digest with TEV enzyme overnight at 20-30°C to obtain double-digested botulinum toxin type A.
[0189] 2. Prepare the buffer solution. First, weigh 0.1835g Zn(OAc)2 with an analytical balance, then add ultrapure water and dilute to 50ml to prepare a 20mM Zn(OAc)2 solution for later use. Weigh 0.5958g HEPEs, 0.0146g NaCl, and 0.0154g DTT with an analytical balance and place them in a 50ml centrifuge tube. Add 50ul of 20mM Zn(OAc)2 solution, then add ultrapure water to about 45ml and mix. Adjust the pH with 1M Na2CO3 solution to 7.4. Finally, use a 50ml volumetric flask to dilute the buffer solution for later use.
[0190] 3. Thaw the CFP-SNAP25(17aa)-YFP substrate protein and CFP-SNAP25(66aa)-YFP substrate protein on ice.
[0191] 4. Turn on the microplate reader and its control computer, and adjust the temperature in the microplate reader reaction chamber to 37 degrees.
[0192] 5. Each system is 50ul. In order to verify the enzymatic cleavage effect of botulinum toxin type A on CFP-SNAP25 (17aa) -YFP substrate and CFP-SNAP25 (66aa) -YFP substrate, different ratios of substrate protein to enzymatic cleavage botulinum toxin type A were set, which were 8:1; 5:1; 2.5:1 respectively.
[0193] 6. Prepare the reaction system in a 1.5 ml EP tube. In the reaction system where the ratio of substrate to cleaved botulinum toxin type A is 8:1, the concentration of cleaved botulinum toxin type A is 140 ug / ml and the substrate concentration is 1120 ug / ml. In the reaction system where the ratio of substrate to cleaved botulinum toxin type A is 5:1, the concentration of cleaved botulinum toxin type A is 140 ug / ml and the substrate concentration is 700 ug / ml. In the reaction system where the ratio of substrate to cleaved botulinum toxin type A is 8:1, the concentration of cleaved botulinum toxin type A is 140 ug / ml and the substrate concentration is 350 ug / ml. The total system is 50 ul. After adding the substrate and cleaved botulinum toxin type A, make up the remaining system with buffer and mix well. Set up two blank controls with only CFP-SNAP25 (17aa) -YFP substrate protein and CFP-SNAP25 (66aa) -YFP substrate protein but no cleaved botulinum toxin type A.
[0194] 7. After mixing, add the reaction system to the 384 ELISA plate and shake the plate in the ELISA reader for 2 minutes.
[0195] 8. After vibrating and mixing, adjust to the reaction program and read the readings every two minutes for three hours. The readings are set to excitation light 433nm, receiving light 476nm, excitation light 433nm, receiving light 526nm. Two different wavelengths of excitation light need to be measured.
[0196] 9. After 3 hours of reading, take out the ELISA plate and add 3ul 0.25% Trypsin to different sample wells to terminate the reaction. After adding 0.25% Trypsin, put the ELISA plate into the ELISA reader and start reading. Read once every minute for half an hour. The reading is set to excitation light 433nm, receiving light 476nm, excitation light 433nm, receiving light 526nm. Two different wavelengths of excitation light need to be measured.
[0197] 10. Experimental result processing: The reading of 476nm of each sample in the reaction program is recorded as X compared with the reading at 526nm, the average of the reading of 476nm in the blank control in the reaction program is recorded as negative, and the average of the reading of 476nm of each sample in the last 5 minutes of the termination reaction is recorded as positive. The concentration of substrate protein FP1-SNAP25-FP2 in the reaction system is recorded as S. At this time, the conversion rate Conversion = S*(X-negative) / (positive-negative). A graph can be drawn based on the conversion rate corresponding to different time points to show the strength of the enzyme activity of botulinum toxin type A (see Figure 3-Figure 6 ).
[0198] Figure 3 The figure shows the difference in conversion rates of two different substrate proteins CFP-SNAP25(17aa)-YFP and CFP-SNAP25(66aa)-YFP in this experiment under different substrate to enzyme ratios. It can be found that the larger the ratio of substrate to enzyme-cleaved botulinum toxin type A (referred to as substrate-enzyme ratio here), the higher the conversion rate. In addition, under the same substrate-enzyme ratio, the conversion rate of substrate CFP-SNAP25(17aa)-YFP is much higher than that of CFP-SNAP25(66aa)-YFP. Figure 4 The difference in conversion rate between substrate proteins CFP-SNAP25(17aa)-YFP and CFP-SNAP25(66aa)-YFP at the same substrate-enzyme ratio was compared, and it was clearly found that CFP-SNAP25(17aa)-YFP had a higher conversion rate. Figure 5 The substrate conversion rates of substrates CFP-SNAP25(17aa)-YFP and CFP-SNAP25(66aa)-YFP at different concentrations are shown respectively. It can be seen that within a certain time range, the substrate conversion rate is linearly related to time, but the linear relationship of substrate CFP-SNAP25(17aa)-YFP is significantly better than that of CFP-SNAP25(66aa)-YFP. Figure 6 It was shown that the conversion rate of substrate 17aa at different concentrations showed a linear relationship within a certain period of time.
[0199] It can be seen that the enzymatic cleavage effect of type A botulinum toxin on the substrate proteins CFP-SNAP25(17aa)-YFP and CFP-SNAP25(66aa)-YFP is in line with expectations, and there is a certain enzymatic cleavage effect on these two substrates, proving that this experiment is feasible. The substrate protein CFP-SNAP25(17aa)-YFP has a better conversion rate and a better linear relationship within a certain time range than the substrate protein CFP-SNAP25(66aa)-YFP.
[0200] Example 3 Comparison of the enzymatic cleavage effect of TEV enzyme on substrate
[0201] 1. (1) preparing double-enzyme-cleaved botulinum toxin type A, as in Example 1;
[0202] (2) To prepare single-digested botulinum toxin type A, type A botulinum toxin was digested with TEV enzyme at 3 mM GSH, 0.3 mM GSSG, and 20-30°C overnight.
[0203] The other steps are similar to those in Example 2, except that the concentration of the substrate protein CFP-SNAP25 (17aa) -YFP in this experiment is 800ug / ml, the concentration of botulinum toxin type A is 140ug / ml (the concentrations of single and double enzyme digestion are both 140ug / ml). The remaining excess volume is supplemented to 50ul with enzyme digestion buffer, and two blank controls are set up with only FP1-SNAP25 (17aa) -FP2 substrate protein added without botulinum toxin type A. The test results are shown in Figure 7-Figure 9 .
[0204] Figure 7 The effects of single-enzyme and double-enzyme digestion of botulinum toxin type A on substrate conversion rates were shown. The results showed that double-enzyme digestion of botulinum toxin type A had an obvious enzymatic digestion effect on the substrate, while single-enzyme digestion (TEV enzyme) of botulinum toxin type A had basically no enzymatic digestion effect on the substrate. Figure 8 It shows that the conversion rate of double-enzyme-cleaved botulinum toxin type A to the substrate presents a linear relationship within a certain time range. Fig. 9 It was shown that botulinum toxin type A with a single enzyme cleavage (TEV enzyme) had essentially no cleavage effect on the substrate.
[0205] Double enzyme digestion of botulinum toxin type A has a good digestion effect on the substrate protein CFP-SNAP25 (17aa) -YFP, while single enzyme digestion of botulinum toxin type A with TEV enzyme has almost no digestion activity on the substrate protein FP1-SNAP25 (17aa) -FP2. This is in line with expectations, because single enzyme digestion does not expose the active site of botulinum toxin type A. Only after double enzyme digestion does the botulinum toxin type A digestion site become exposed, and then botulinum toxin type A becomes active.
[0206] Example 4 Comparison of the enzymatic cleavage effect of KLK5 enzyme on substrate
[0207] This experiment is similar to Example 3, the main difference is that the single-enzyme-cleaved botulinum toxin type A is replaced with KLK5 enzyme, and the concentration of KLK5 enzyme is consistent with the concentration of KLK5 enzyme in the preparation of double-enzyme-cleaved botulinum toxin type A, both of which are 1.4μg / ml. The other steps are similar to Example 3, and the results are shown in Figure 10-11 .
[0208] This experiment proved that the double-enzyme-cleaved botulinum toxin type A and KLK5 enzyme had an enzymatic effect on the substrate protein CFP-SNAP25(17aa)-YFP, but Fig.10 It can be seen that the enzymatic cleavage efficiency of double-enzyme-cleaved botulinum toxin type A on substrate protein is obviously higher than that of KLK5. This shows that the entire enzymatic cleavage system is still feasible, but the enzymatic cleavage system needs to be optimized, and the enzymatic activity of KLK5 needs to be suppressed as much as possible, while also ensuring that the double-enzyme-cleaved botulinum toxin type A has enzymatic cleavage activity.
[0209] Example 5 Testing the effect of different concentrations of Tween80 on the activity of double-enzyme toxin
[0210] Buffer preparation: Prepare the toxin digestion buffer. First, weigh 0.1835 g Zn(OAc) using an analytical balance.
[0211] 2 Then add ultrapure water to make up to 50 ml to prepare 20 mM Zn(OAc) 2 The solution is ready for use. Use an analytical balance to weigh 0.5958 g of HEPEs, 0.0146 g of NaCl, and 0.0154 g of DTT and place them in a 50 ml centrifuge tube, and add 500 ul of 20 mM Zn(OAc). 2 Solution (at this time, the solution Zn(OAc) 2 The final concentration is 200uM), then add ultrapure water to about 45ml and mix well. 2 CO 3 Adjust the pH of the solution to 7.4, and finally use a 50ml volumetric flask to make up the enzyme digestion buffer for use. After the volume is made up, take 10ml of the enzyme digestion buffer system without Tween80 and add it to 5 empty tubes, then use a pipette to take the corresponding volume of Tween80 and add it to the enzyme digestion reaction system, and prepare it to 0.01%
[0212] The toxin enzyme digestion buffer system of Tween80, 0.1% Tween80, 0.5% Tween80, 0.8% Tween80 and 1% Tween80 is ready for use.
[0213] The other steps are similar to those in Example 4. For specific results, see Fig.19 , Fig.19 The example shows that the double-enzyme toxin has an obvious enzymatic cleavage effect on the substrate in the enzymatic cleavage system containing different concentrations of Tween80. This example verifies that the double-enzyme toxin has an enzymatic cleavage effect on the substrate protein CFP-SNAP25 (17aa) -YFP in the enzymatic cleavage system with different concentrations of Tween80, and the enzymatic cleavage efficiency is the highest when the Tween80 concentration is 0.1%.
[0214] Example 6 Effect of adding Tween on the activity of KLK5 enzyme
[0215] This experiment is similar to Example 4, the main difference is that 0.1% Tween80 was added to the reaction system, and the other steps were similar to Example 4. The results are shown in Figure 12-13 .
[0216] Fig.12 It was shown that the conversion rate of double-digested botulinum toxin type A to substrate protein in an enzyme digestion system containing Tween80 showed a linear relationship within a certain time range. Fig.13 It is shown that in the new enzyme digestion system containing Tween80, the KLK5 enzyme has basically no enzyme digestion effect on the substrate protein. This example verifies that in the enzyme digestion system containing Tween80, the double-enzyme-cleaved botulinum toxin type A has an enzyme digestion effect on the substrate protein CFP-SNAP25 (17aa) -YFP, while the KLK5 enzyme has no enzyme digestion effect on the substrate protein CFP-SNAP25 (17aa) -YFP substrate. It shows that the addition of Tween has an inhibitory effect on the activity of the KLK5 enzyme, but does not affect the activity of the double-enzyme-cleaved botulinum toxin type A.
[0217] Example 7 Testing of 5 different single enzyme-cutting botulinum toxin enzymes and optimizing the reaction system
[0218] Similar to the above-mentioned Example 3, the difference is that several groups of different single enzyme cleavage toxins are added, single enzyme cleavage FA: 336ug / mL; FB: 277ug / mL; FC: 110ug / mL; FD: 427ug / mL; HD: 100ug / mL. Among them, FA, FB, FC, FD and HD are all botulinum toxins included in the present invention, and the difference from the botulinum toxin in Example 3 is that there are two first enzyme cleavage sites for FA, FB, FC, and FD, and all of them have KLK5 cleavage sites, and the other first enzyme cleavage sites are all from Furin protease cleavage sites (RRSV, RRKR, RRSV, RRSV, respectively), and the second enzyme cleavage sites are all the same (TEV enzyme cleavage), that is, FA, FB, FC, FD and HD are all single enzyme cleavage by TEV enzyme; the first cleavage site of HD is only KLK5.
[0219] Preparation of buffer: Use an analytical balance to weigh 0.5958 g of HEPEs, 0.0146 g of NaCl, and 0.0154 g of DTT and place them in a 50 ml centrifuge tube, and add 50 ul of 20 mM Zn(OAc) 2 Solution, add 0.1% Tween80 (add 50ul 100% Tween80 to 50ml system) and then add ultrapure water to about 45ml and mix well. In addition, prepare other buffer systems and test buffer system 2. All other conditions remain unchanged and Zn 2+ The concentration was increased 10 times to 200uM; the buffer system 3 was tested without Tween80, and all other conditions remained unchanged, the pH was adjusted to 5 with 1M HCL, and the buffer system 4 was tested without Tween80, and all other conditions remained unchanged with the addition of 1% BSA; the buffer system 5 was tested without Tween80, and all other conditions remained unchanged with the addition of 1% BSA and 1mM PMSF.
[0220] Other conditions and steps are similar to those in Example 4. Fig. 20 , Figure 14-15 .
[0221] Fig. 20 It was shown that in the enzyme cleavage system containing Tween80, the double-enzyme-cleaved botulinum toxin had an obvious enzymatic cleavage effect on the substrate, while the single-enzyme-cleaved FA, FB, FC, FD, and HD botulinum toxins had no enzymatic cleavage effect on the substrate, and the KLK5 enzyme had basically no enzymatic activity in the enzyme cleavage system containing Tween80.
[0222] Fig.14 It was shown that the addition of BSA and PMSF to the optimized reaction system could significantly improve the enzymatic activity of double-digested botulinum toxin type A, and also enhance the cleavage activity of KLK5 enzyme. Fig.15 The effect of increased zinc ion concentration in the enzyme cleavage system on the cleavage of double-enzyme-cleaved botulinum toxin type A substrate is demonstrated.
[0223] This example once again verifies that the double-enzyme-cutting botulinum toxin type A has an enzymatic cleavage effect on the substrate protein CFP-SNAP25 (17aa) -YFP in the enzymatic cleavage system containing Tween80, while the KLK5 enzyme has basically no enzymatic cleavage effect on the substrate protein CFP-SNAP25 (17aa) -YFP, and the single-enzyme-cutting botulinum toxin type A has no enzymatic cleavage effect on the substrate protein CFP-SNAP25 (17aa) -YFP in the enzymatic cleavage system containing Tween80. In addition, adding BSA to the enzymatic cleavage system can enhance the enzymatic activity of the double-enzyme-cutting botulinum toxin type A, but it also enhances the enzymatic activity of KLK5. In addition, increasing the zinc ion concentration in the reaction system has little effect on the enzyme activity. In addition, the enzymatic activity of botulinum toxin type A is also significantly improved when the pH of the reaction system is 5.
[0224] Example 8 Testing of botulinum toxin type A enzyme activity under acidic conditions and at different DTT concentrations
[0225] Preparation of buffer: Use an analytical balance to weigh 0.5958 g of HEPEs and 0.0146 g of NaCl, add them to a 50 ml centrifuge tube, and add 50 ul of 20 mM Zn(OAc) 2 Solution, then add ultrapure water to about 45ml and mix well, then adjust the pH with 1M HCl solution to 5, and finally use a 50ml volumetric flask to make up the enzyme digestion buffer for use. After the volume is set, take 10ml of the enzyme digestion buffer system without DTT and add it to 4 empty tubes, then weigh the corresponding amount of DTT powder and add it to the enzyme digestion reaction system, and configure it into 0mM DTT, 2mM DTT, 5mM DTT, and 10mM DTT type A botulinum toxin enzyme digestion buffer systems respectively.
[0226] The other steps are similar to those in Example 4. Fig.16 .Depend on Fig.16 It can be seen that in the enzyme digestion system with different concentrations of DTT at pH = 5 (without Tween80), the double-enzyme-cutting botulinum toxin type A has a significant enzymatic digestion effect on the substrate protein, and KLK5 also has a significant enzymatic digestion effect on the substrate protein in the enzyme digestion system with different concentrations of DTT at pH = 5 (without Tween80). However, whether it is the double-enzyme-cutting botulinum toxin type A or the KLK5 enzyme, the enzymatic digestion efficiency of the substrate protein decreases with the increase of DTT concentration, and there is basically no enzyme activity when the DTT concentration is greater than 5mM.
[0227] This example verifies that in the enzyme digestion system without Tween80, the double-digested botulinum toxin type A and the KLK5 enzyme have an enzyme digestion effect on the substrate protein CFP-SNAP25 (17aa) -YFP, which further verifies the inhibitory effect of Tween80 on the KLK5 enzyme. This example verifies that at pH = 5, not only the enzyme activity of the double-digested botulinum toxin type A is enhanced, but also the enzyme activity of KLK5 is significantly enhanced, so the enzyme digestion system under acidic conditions is not desirable for the entire experiment. Overall, the system has a better effect on the entire enzyme digestion system under weak alkaline conditions (such as pH = 7.4). In addition, by changing the concentration of DTT in the enzyme cleavage system, it can be found that with the increase of DTT concentration, the enzymatic cleavage activity of double-enzyme-cut botulinum toxin type A and KLK5 enzyme on the substrate protein becomes lower and lower. When the DTT concentration in the enzyme cleavage system is higher than 5mM, the double-enzyme-cut botulinum toxin type A and KLK5 enzyme have basically no enzymatic cleavage activity on the substrate. Therefore, as the DTT concentration increases, it also has an inhibitory effect on the activity of the peptidase. However, since botulinum toxin type A has 5 pairs of disulfide bonds, adding DTT to the reaction system still has a certain promoting effect on maintaining its structural stability.
[0228] Example 9 Testing the activity of botulinum toxin type A at different DTT concentrations in a system containing Tween 80
[0229] Buffer preparation: Prepare the botulinum toxin type A digestion buffer. First, weigh 0.1835 g Zn(OAc) using an analytical balance. 2 Then add ultrapure water to make up to 50 ml to prepare 20 mM Zn(OAc) 2 The solution is ready for use. Use an analytical balance to weigh 0.5958 g of HEPEs and 0.0146 g of NaCl respectively and place them in a 50 ml centrifuge tube, and add 500 ul of 20 mM Zn(OAc)2 solution (the solution Zn(OAc) 2 The final concentration is 200uM), then add 0.1% Tween80 (50ul 100% Tween80 is added to 50ml system) and then add ultrapure water to about 45ml and mix well. 2 CO 3 Adjust the pH of the solution to 7.4, and finally use a 50ml volumetric flask to make up the enzyme digestion buffer for use. After the volume is made up, take 10ml of the enzyme digestion buffer system without DTT and add it to 4 empty tubes, then weigh the corresponding amount of DTT powder and add it to the enzyme digestion reaction system, and respectively configure it into 0mM DTT, 0.5mM DTT, 1mM DTT, 2mM DTT, 5mM DTT, and 10mM DTT type A botulinum toxin enzyme digestion buffer system for use.
[0230] The other steps are similar to those in Example 4. Figure 17-Figure 18 , Fig.17 It was shown that in the enzyme cleavage system containing Tween80, the double-enzyme-cleaved botulinum toxin type A had a significant enzymatic cleavage effect on the substrate protein, while KLK5 had basically no enzymatic cleavage effect on the substrate protein in the enzyme cleavage system containing Tween80, that is, it had basically no enzyme activity. Fig.18 The results showed that KLK5 had basically no enzymatic activity in the enzyme cleavage system containing Tween80, but the enzymatic activity of double-enzyme-cleaved botulinum toxin type A in the enzyme cleavage system containing Tween80 weakened with the increase of DTT concentration, and when the DTT concentration was greater than 5mM, the enzymatic activity of double-enzyme-cleaved botulinum toxin type A was also basically inhibited.
[0231] This example further verifies that the double-digested botulinum toxin type A has a digestion effect on the substrate protein CFP-SNAP25 (17aa) -YFP in the digestion system containing Tween80, while the KLK5 enzyme has basically no digestion effect on the substrate protein CFP-SNAP25 (17aa) -YFP in the digestion system containing Tween80, which once again verifies that Tween80 does have an inhibitory effect on the enzymatic activity of the KLK5 enzyme. In addition, Tween80 does not affect the enzymatic activity of the double-digested botulinum toxin type A, and the entire digestion system containing Tween80 is stable. In addition, in the digestion system with different DTT concentrations, as the DTT concentration in the digestion system increases, the enzymatic activity of the double-digested botulinum toxin type A also decreases, which shows that the concentration of DTT has an inhibitory effect on the enzymatic activity of the double-digested botulinum toxin type A, but also inhibits the enzymatic activity of KLK5. When the DTT concentration is greater than 5mM, the enzymatic activity of the double-digested botulinum toxin type A is also substantially inhibited.
[0232] Table 2 Sequences involved in the present invention
[0233]
[0234]
[0235]
[0236]
[0237]
[0238]
[0239]
[0240]
[0241]
[0242]
[0243] Based on the above ideal embodiments of this application, the relevant staff can make various changes and modifications without departing from the technical concept of this application through the above description. The technical scope of this application is not limited to the content in the specification, and its technical scope must be determined according to the scope of the claims.
Claims
1. A system for detecting toxin activity, characterized in that: The invention comprises the following components: one or more of HEPES, NaCl, DTT, surfactant or Zn(OAc)2; preferably, the surfactant is selected from one or more of triton x-100, SDS, Span or Tween.
2. A system for detecting toxin activity according to claim 1, characterized in that: The components also include an enzymatic toxin and a substrate protein that are active when enzymatically cleaved by a first specific protease.
3. A system for detecting toxin activity according to claim 1 or 2, characterized in that: The toxin is selected from Clostridial toxins; preferably botulinum toxin; more preferably botulinum toxin type A, B, C, D, E, F or G.
4. A system for detecting toxin activity according to any one of claims 1 to 3, characterized in that: The first specific protease is selected from one or more of epidermal specific kallikrein (KLKs), SASPase protease, Caspase protease, and Furin protease; further preferably, the KLKs are selected from any one or more of KLK1 to KLK15; more preferably, the enzyme is selected from KLK5 or KLK7 enzyme.
5. A system for detecting toxin activity according to claim 4, characterized in that: The cleaved toxin is also cleaved by a second specific protease, which includes non-human enterokinase, tobacco etch virus protease (TEV enzyme), a protease derived from Bacillus subtilus, a protease derived from Bacillus amyliquifaciens, a protease derived from a rhinovirus, papain, a homolog of insect papain, or a homolog of crustacean papain; preferably TEV enzyme.
6. A system for detecting toxin activity according to any one of claims 1 to 5, characterized in that: The substrate protein contains a cleavage site that can be specifically cleaved by the cleavage toxin; preferably, the cleavage site is derived from the SNARE protein; more preferably, it is derived from the SNAP25 protein.
7. A system for detecting toxin activity according to claim 6, characterized in that: The substrate protein is also fused with a fluorescent protein.
8. A system for detecting toxin activity according to claim 6 or 7, characterized in that: The restriction site is selected from SNAP25 (naa), wherein aa refers to amino acids and n refers to the number of amino acids; further preferably, the sequence of SNAP25 (naa) is SEQ ID NO: 24 or SEQ ID NO: 25; or it is a polypeptide having ≥85%, ≥90%, ≥95%, ≥97%, ≥98% or ≥99% homology with the amino acid sequence shown in SEQ ID NO: 24 or SEQ ID NO: 25, and having the same activity as SEQ ID NO: 24 or SEQ ID NO:
25.
9. A system for detecting toxin activity according to any one of claims 1 to 8, characterized in that: The fluorescent protein is selected from cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), green fluorescent protein (GFP), red fluorescent protein (RFP), orange fluorescent protein (OFP) or blue fluorescent protein (BFP); further preferably, the fluorescent protein is selected from two or more.
10. A system for detecting toxin activity according to any one of claims 1 to 9, characterized in that: The substrate protein is selected from FP1-SNAP25(naa)-FP2, wherein FP1 and FP2 both refer to the fluorescent protein described in claim 9, and FP1 and FP2 are different.
11. A system for detecting toxin activity according to any one of claims 1 to 10, characterized in that: The substrate protein is selected from CFP-SNAP25(naa)-YFP; preferably, the sequence of CFP is SEQ ID NO:27, or a polypeptide having ≥85%, ≥90%, ≥95%, ≥97%, ≥98% or ≥99% homology with the amino acid sequence shown in SEQ ID NO:27, and having the same activity as the sequence of SEQ ID NO:27; further preferably, the sequence of YFP is SEQ ID NO:28, or a polypeptide having ≥85%, ≥90%, ≥95%, ≥97%, ≥98% or ≥99% homology with the amino acid sequence shown in SEQ ID NO:28, and having the same activity as the sequence of SEQ ID NO:28; more preferably, the sequence of the substrate protein is SEQ ID NO:29 or SEQ ID NO:30, or a polypeptide having ≥85%, ≥90%, ≥95%, ≥97%, ≥98% or ≥99% homology with the amino acid sequence shown in SEQ ID NO:28, and having the same activity as the sequence of SEQ ID NO:
28. A polypeptide having an amino acid sequence with ≥85%, ≥90%, ≥95%, ≥97%, ≥98% or ≥99% homology as SEQ ID NO: 29 or SEQ ID NO: 30, and having the same activity as SEQ ID NO: 29 or SEQ ID NO:
30.
12. A system for detecting toxin activity according to any one of claims 1 to 11, characterized in that: The system also has a combination of any one or more of the following characteristics: the concentration of HEPES is 0-1M, the concentration of NaCl is 0-100mM, the concentration of DTT is 0-10mM, the volume concentration of Tween is 0-1%, the concentration of Zn(OAc)2 is 0-1mM, the concentration of substrate protein is 1-2mg / ml, and the concentration of enzyme-cleaved toxin is 1-500μg / ml.
13. A system for detecting toxin activity according to claim 12, characterized in that: The system also has a combination of any one or more of the following characteristics: the concentration of the HEPES is 10-200mM, the concentration of the NaCl is 1-10mM, the concentration of the DTT is 0-5mM, the volume concentration of the Tween is 0.01-0.5%, the concentration of the Zn(OAc)2 is 0.1-0.5mM, the concentration of the substrate protein is 0.1-2mg / ml, and the concentration of the enzyme-cleaved toxin is 10-200μg / ml; further preferably, the concentration of the HEPES is 50-100mM, the concentration of the NaCl is 1-5mM, the concentration of the DTT is 0.5-2mM, the volume concentration of the Tween is 0.01-0.1%, the concentration of the Zn(OAc)2 is 0.1-0.2mM, the concentration of the substrate protein is 0.1-0.8mg / ml, and the concentration of the enzyme-cleaved toxin is 10-140μg / ml.
14. A method for detecting toxin activity, characterized in that: The system described in any one of claims 1-13 is used to detect the activity of the toxin by a fluorescence test method. Preferably, before the toxin is detected by the system, it is an enzymatic toxin as described in any one of claims 2-5 obtained by enzymatic cleavage treatment.
15. A method for detecting toxin activity according to claim 14, characterized in that: The fluorescence testing method adopts the fluorescence resonance energy transfer (FRET) method.
16. A method for detecting toxin activity according to claim 14 or 15, characterized in that: The detection method further comprises: (1) using a specific protease to cleave the toxin to obtain the cleaved toxin; (2) preparing a reaction system, wherein the reaction system comprises one or more of HEPES, NaCl, DTT, Tween or Zn(OAc)2, the cleaved toxin and a substrate protein; (3) mixing the reaction system of step (2) uniformly, adding it to an ELISA plate and performing on-machine detection; (4) after the on-machine detection is completed, adding Trypsin to terminate the reaction, performing on-machine reading, and calculating the enzyme activity of the toxin based on the ratio of different fluorescence values; the specific protease is selected from the first specific protease described in claim 4 and / or the second specific protease described in claim 5.
17. A method for detecting toxin activity according to claim 16, characterized in that: The concentration of the enzyme is 0.1-10 μg / ml, preferably 1-5 μg / ml, and more preferably 1.4-2 μg / ml.
18. A method for detecting toxin activity according to claim 16 or 17, characterized in that: The buffer is alkaline; preferably, the pH value of the buffer is 7.0-8.0; more preferably, the pH value is 7.0-7.5; and most preferably, the pH value is 7.4.
Citation Information
Patent Citations
Kit for in vitro synthesis of protein and preparation method
CN106978349A
Protein synthesis system for in-vitro protein synthesis, kit and preparation method for protein through in-vitro synthesis
CN108535489A
Synthesis system, preparation, kit and preparation method of in-vitro DNA-to-Protein (D2P)
CN108642076A
Novel fusion protein preparation method and application of novel fusion protein for increasing protein synthesis
CN108690139A
Method for regulating in-vitro biosynthetic activity by knocking out nuclease system
CN108949801A
Cited By
FRET-based caspase-1 responsive fluorescent probe, preparation method, application and product
CN121449684A
A caspase-1 responsive fluorescent probe based on FRET, preparation method, application and product
CN121449684B
